U.S. markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.28+0.31 (+0.94%)
At close: 04:00PM EST
33.50 +0.22 (+0.66%)
After hours: 04:20PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close32.97
Bid33.20 x 1100
Ask33.50 x 800
Day's Range32.60 - 33.76
52 Week Range26.81 - 56.25
Avg. Volume1,016,411
Market Cap3.788B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateFeb 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ARWR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arrowhead Pharmaceuticals, Inc.
    ARWR: Lowering target price to $35.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Business Wire

    Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

    PASADENA, Calif., January 25, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.

  • Simply Wall St.

    A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Arrowhead...

  • Zacks Small Cap Research

    ARWR: Encouraging Results for Phase 2 SEQUOIA Trial…

    By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT On January 9, 2023, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced topline results for the Phase 2 SEQUOIA trial of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD) liver disease. A copy of the slides discussing the results can be found here . The SEQUOIA trial is a placebo